Logo image of NNVC

NANOVIRICIDES INC (NNVC) Stock Fundamental Analysis

USA - NYSEARCA:NNVC - US6300873022 - Common Stock

1.5 USD
-0.09 (-5.66%)
Last: 11/12/2025, 8:04:00 PM
1.51 USD
+0.01 (+0.67%)
After Hours: 11/12/2025, 8:04:00 PM
Fundamental Rating

2

Overall NNVC gets a fundamental rating of 2 out of 10. We evaluated NNVC against 531 industry peers in the Biotechnology industry. The financial health of NNVC is average, but there are quite some concerns on its profitability. NNVC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year NNVC has reported negative net income.
NNVC had a negative operating cash flow in the past year.
In the past 5 years NNVC always reported negative net income.
In the past 5 years NNVC always reported negative operating cash flow.
NNVC Yearly Net Income VS EBIT VS OCF VS FCFNNVC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

NNVC's Return On Assets of -107.29% is on the low side compared to the rest of the industry. NNVC is outperformed by 77.40% of its industry peers.
NNVC has a Return On Equity of -125.93%. This is in the lower half of the industry: NNVC underperforms 60.08% of its industry peers.
Industry RankSector Rank
ROA -107.29%
ROE -125.93%
ROIC N/A
ROA(3y)-38.17%
ROA(5y)-46.67%
ROE(3y)-40.8%
ROE(5y)-52.73%
ROIC(3y)N/A
ROIC(5y)N/A
NNVC Yearly ROA, ROE, ROICNNVC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

NNVC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NNVC Yearly Profit, Operating, Gross MarginsNNVC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, NNVC has more shares outstanding
NNVC has more shares outstanding than it did 5 years ago.
NNVC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NNVC Yearly Shares OutstandingNNVC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
NNVC Yearly Total Debt VS Total AssetsNNVC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

2.2 Solvency

NNVC has an Altman-Z score of -14.42. This is a bad value and indicates that NNVC is not financially healthy and even has some risk of bankruptcy.
NNVC's Altman-Z score of -14.42 is on the low side compared to the rest of the industry. NNVC is outperformed by 78.53% of its industry peers.
NNVC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.42
ROIC/WACCN/A
WACCN/A
NNVC Yearly LT Debt VS Equity VS FCFNNVC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 1.28 indicates that NNVC should not have too much problems paying its short term obligations.
NNVC has a Current ratio of 1.28. This is amonst the worse of the industry: NNVC underperforms 85.12% of its industry peers.
A Quick Ratio of 1.28 indicates that NNVC should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.28, NNVC is doing worse than 84.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 1.28
NNVC Yearly Current Assets VS Current LiabilitesNNVC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

1

3. Growth

3.1 Past

NNVC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.30%, which is quite good.
EPS 1Y (TTM)9.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.12% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-12.5%
EPS Next 2Y2.47%
EPS Next 3Y1.64%
EPS Next 5Y8.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NNVC Yearly Revenue VS EstimatesNNVC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
NNVC Yearly EPS VS EstimatesNNVC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

0

4. Valuation

4.1 Price/Earnings Ratio

NNVC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NNVC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NNVC Price Earnings VS Forward Price EarningsNNVC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NNVC Per share dataNNVC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.47%
EPS Next 3Y1.64%

0

5. Dividend

5.1 Amount

NNVC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NANOVIRICIDES INC

NYSEARCA:NNVC (11/12/2025, 8:04:00 PM)

After market: 1.51 +0.01 (+0.67%)

1.5

-0.09 (-5.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-29 2025-09-29/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners8.31%
Inst Owner Change7.28%
Ins Owners0.6%
Ins Owner Change0%
Market Cap26.14M
Revenue(TTM)N/A
Net Income(TTM)-9.47M
Analysts82.86
Price TargetN/A
Short Float %0.27%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.48
P/tB 3.63
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS0.43
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -107.29%
ROE -125.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.17%
ROA(5y)-46.67%
ROE(3y)-40.8%
ROE(5y)-52.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 1.28
Altman-Z -14.42
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)32.55%
Cap/Depr(5y)21.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.73%
EPS Next Y-12.5%
EPS Next 2Y2.47%
EPS Next 3Y1.64%
EPS Next 5Y8.12%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.74%
OCF growth 3YN/A
OCF growth 5YN/A

NANOVIRICIDES INC / NNVC FAQ

What is the fundamental rating for NNVC stock?

ChartMill assigns a fundamental rating of 2 / 10 to NNVC.


What is the valuation status of NANOVIRICIDES INC (NNVC) stock?

ChartMill assigns a valuation rating of 0 / 10 to NANOVIRICIDES INC (NNVC). This can be considered as Overvalued.


What is the profitability of NNVC stock?

NANOVIRICIDES INC (NNVC) has a profitability rating of 0 / 10.


How financially healthy is NANOVIRICIDES INC?

The financial health rating of NANOVIRICIDES INC (NNVC) is 5 / 10.